TREM2 and Alzheimer disease: Immunosenescence, in particular, may represent an important source of heterogeneity for drugs that affect cell survival pathways (e.g., CSF1R and TREM2, as described above) and a therapeutic target for AD and other conditions for which neuroinflammation may drive the disease process [173, 174].